nVerses Capital’s Capricor Therapeutics CAPR Stock Holding History

nVerses Capital’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Buy	+13,951	New	+$423K	0.52%	36

Other funds holding CAPR

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BDF

Black Diamond Financial Towson, Maryland $1.13B AUM 22.3% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

FRM

Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return

nVerses Capital's CAPR Position: Q2 2026 in Review

nVerses Capital opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 13,951 shares worth $336K. The stake represents 0.52% of the portfolio and ranks #36 among its holdings.

32 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

nVerses Capital held 13,951 shares of Capricor Therapeutics worth $336K as of Q2 2026.
Capricor Therapeutics was a new nVerses Capital position in Q2 2026.
Capricor Therapeutics made up 0.52% of nVerses Capital's portfolio in Q2 2026, its #36 holding.
32 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.